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Serially diluted and agitated (SAD) drugs available commercially are in use with great faith because of the astonishing results they
produce. The scientiﬁc viewpoint attached to the centuries-old therapy with SAD drugs, as in homeopathy, remained doubtful
for want of appropriate research and insuﬃcient evidence base. The conﬂicting points related to SAD drug mostly related to the
level of concentrations/dilutions, use of drug in contradictory clinical conditions compared to the modern system of medicine,
identiﬁcation of medicinally active ingredient in concentrations and dilutions used in commercially available SAD drugs, and lack
of laboratory-based pharmacological data vis-` a-vis modern medicine. Modus operandi of SAD drug is also unknown. To address
some of these issues an analytical study was carried out wherein commercially available SAD drug Digitalis purpurea, commonly
used in diﬀerent systems of medicine, was put to test. Various concentrations of commercially available Digitalis purpurea were
analyzedusinganalyticalmethods:cyclicvoltammetry,emissionspectroscopy,andUV-VISspectroscopy.Theseanalyticalmethods
apparently identiﬁed the medicinal ingredients and eﬀect of serial dilution in commercial preparation of the drugs.
1.Introduction
The drug Digitalis,a ne x t r a c to fDigitalis purpurea,F o x g l o v e
plant, is in use since long. Medical practitioners, namely,
William Withering, 1785 [1] and Hahnemann, 1803 [2], had
introduced the drug in their respective systems of medicine.
Out of about thirty known organic compounds of Digitalis
purpurea only 4–6 are medicinally active components com-
prising of Digoxin, Digitoxigenin, Digoxigenin,a n dSaponins.
Digitalis purpurea derivatives are used in treatment of dis-
eases like heart failure, arrhythmia, neurological diseases
and also being tried as antitumor [3]. Digoxin (C41H64O14)
is 300 times more potent than the powder prepared from
Digitalis purpurea. It has a molecular weight of 780.95, and
the absolute bioavailability of Digoxin intravenous injection
is 100%. Time of onset of the eﬀect of Digoxin after
intra-venous injection is 5–30 minutes, Patients maintained
on Digoxin may also use ultradiluted preparations of the
same, ultimately increasing the body burden of Digoxin.
Saturated extract of an aqueous ethanol mixture is used to
prepare serial dilution of the drug Digitalis purpurea and
is represented by the suﬃx“ θ”. Serial dilutions also are
referred to as potencies “1c” or “1” in centesimal scale,
which means that one part of the “θ” saturated extract of
the drug is mixed to make 100 parts of aqueous ethanol
mixture and succused. When the same process is repeated
6 times, by adding 1 part of the previous potency in 99
parts of aqueous ethanol mixture and succused, after each
stage starting from the ﬁrst dilution for the next 5 times,
“6c” or “6” potency is obtained. Presently, it is not possible
to detect the serially ultradiluted drug Digitalis purpurea in
biological samples. However, attempts are on to ﬁnd the2 Journal of Analytical Methods in Chemistry
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Figure 1: Structure of Digoxin.
“evidence base” of serially ultradiluted drugs. Methods to
identify the medicinally active ingredient in ultradiluted
drugshavebeenattemptedsparingly[4].Theinvestigationof
homeopathic drugs is extremely interesting and challenging
andfrom that point of viewshows novelty. Digitalispurpurea
is readily available commercially, in serial dilutions prepared
with aqueous alcohol (91.4%) as diluent. The serial dilution
12c of the drug, at a ratio 10−24, has a 60% probability of
containing one molecule of original material if one mole
of the original substance was used. Digitalis-like toxicity
(Digitalis intoxication) results from an overdose of the drug,
consumption of Digitalis purpurea plant products, and from
toad skin (another animal source: butterﬂies) [5]. Digitalis
intoxicationcausesanorexia,nausea,vomiting,anddiarrhea,
jaundiced or yellow vision, appearance of blurred outlines,
reduced heart rate, and weight loss. It is also necessary to
evaluate the quality of the drug in solutions/dilutions. This
motivated us and necessitated detection of Digitalis purpurea
inserialdilutions.AttemptshadbeenmadetodetectDigoxin
in solutions by various methods [6].
T h ep r i m a r ya i mo ft h i sw o r ki st od e t e c tt h ep r e s e n c e
of Digitalis purpurea (DP), Digoxin, and/or Digoxin-like
substance in serial ultradilutions using ﬂuorescence spec-
troscopyandcyclicvoltametryforcomparisonofthecompo-
nents of Digitalis purpurea, which has intrinsic ﬂuorescence.
This original research work oﬀers additional data for
improving standardization of ultradiluted drugs in com-
plementary/alternative system of medicine. Two analytical
methods, ﬂuorescence spectroscopy and cyclic voltametry
(CV), of the ultradiluted drugs Digitalis purpurea vis-` a-vis
Digoxin (0.25mg/mL) were carried out for detection of the
Digoxin-like substance.
The methods reported here are highly selective, sensitive,
stable, and reproducible. The structure of medicinally active
ingredient Digoxin is given in Figure 1. The compound is
known to be hydrophobic in nature, but the sugar moiety
attached to the compound changes its solubility. It is found
to be somewhat soluble in chloroform in its purest form.
2.Methodology
The drug Digitalis purpurea used in this work in poten-
cies/ultradilutions θ, 6, 30, and 200 were procured from M/s
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Figure 2: Emission spectra obtained by analytical ﬂuorescence
spectroscopyofnaturalproductDigitalispurpureaderivativehaving
the purest derivative component Digoxin (B) showing emission
maxima at 318nm, showing a relative intensity of 4.5 × 106.
C6: Digitalis purpurea 6 having emission maxima at 357nm and
374nm showing a relative intensity of 13 × 106 and 12 × 106.
D30: Digitalis purpurea 30 having emission maxima at 357nm and
374nm showing a relative intensity of 16×106 and 14.5×106. E200
= Digitalis purpurea 200 having emission maxima at 357nm and
374nm, showing a relative intensity of ∼ 10 ×106 and 9 ×106.
Hahnemann Publishing Company Pvt Ltd, Kolkata, India. It
was prepared with contaminant free, for example, acetone-
free aqueous alcohol (91.4% ethanol and glass double
distilled water mixture). The drugs were manufactured as
per Indian Homeopathic Pharmacopoeia. The commercially
available Digoxin with concentration 0.25mg/mL (Samarth
Pharma) was procured from the local medicine vendor for
the present studies. Rectiﬁed spirit/ethanol manufactured by
Bengal Chemicals & Pharmaceuticals, India, was used.
All the experiments were carried out to ensure repro-
ducibility. For constrains attempt to detect the upper limit
could not be carried out, although we carried out the
voltammetric measurements using saturated extracts of the
drug. It is well known that the Lambert-Beer Law is valid
for dilute solutions and the ﬂuorescence intensity is linearly
related to concentration of dilute solutions.
The UV-VIS and emission spectra were measured using
a Shimadzu (model no. UV-1601) spectrophotometer, and
a Spex-Fluorolog-3 (model no. FL3-11) spectroﬂuorimeter
respectively. The UV-VIS maximum for Digoxin is calcu-
lated to be at 255nm and, in another experimental study,
published earlier, an absorption maximum was found to be
251nm by the authors [7]. Emission spectra were obtained
by analytical ﬂuorescence spectroscopy of natural product
Digitalispurpurea(inultradilutions)anditspurestderivative
component Digoxin.
All the voltammetric measurements were carried out
using a computer-controlled CHI643B electrochemical ana-
lyzer attached with a Faraday cage/picoampere booster
(CH Instruments, Austin, TX). A two-compartment three-
electrode cell with glassy carbon (GC) and a polycrystalline
gold (Au) working electrode (2mm dia, BAS, USA), a
platinum wire auxiliary electrode, and an Ag/AgCl (3M KCl)
reference electrode were used in the measurements.Journal of Analytical Methods in Chemistry 3
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Figure 3: (a) Voltammograms of ethanol (91.4%), (b) Digoxin, (c) Digitalis purpurea θ,( d )Digitalis purpurea 6, (e) Digitalis purpurea 30,
and (f) Digitalis purpurea 200.4 Journal of Analytical Methods in Chemistry
3. Electrode Modiﬁcation for
Voltammetric Measurements
Polycrystalline Au was polished well with alumina powder
(0.06μm) and sonicated repeatedly in water for 8–10min.
The polished Au electrode, of geometrical surface area
0.031cm2, was cleaned electrochemically by cycling the
potential between—0.2 and 1.5V in 0.25MH2SO4 at the
scan rate of 10V/s for ∼10min, until the characteristic cyclic
voltammograms for a clean Au electrode were obtained, and
the same was used as working electrode. All the experi-
ments were carried out in 0.1MNa2HPO4 (pH11). Digitalis
purpurea in serial dilution and its purest derivative Digoxin
were used in all the following studies. The voltammograms
of Digitalis purpurea Q, 6C, 30C, and 200C dilutions, and
Digoxin were obtained using pairs of Au electrodes at pH 11,
at scan rate of 100mV/s. 100μL of samples was used.
4. Result andDiscussion
The ﬂuorescence is likely to be due to α,β-unsaturated
lactone present in the compound. The ﬂuorescence spec-
trum of the compound is taken at diﬀerent dilutions in
aqueous ethanol. In all the emission studies, the samples
were excited at 255nm. The emission spectra of diﬀerent
dilutions are shown as C, D, and E, and purest medicinally
active ingredient Digoxin is shown as B in Figure 2. These
ﬂuorescence spectra revealed that Digoxin component shows
a structureless ﬂuorescent with emission maxima at 318nm
with a relative intensity of 4.5 × 106. The emission spectra
of Digitalis purpurea 6 are shown in Figure 2 as C6. In this
casethestructurelessemissionisfoundtobemodiﬁed witha
semistructuredemissionwithmaximaat357nmand374nm
and further a shoulder at about 318nm remained, which
could be due to the original B (Digoxin). The appearance of
additional bands at 357 and 374nm may be ascribed to loss
of self-quenching or dissociation of component substance
due to serial dilution, and these bands showed an increase
in intensity with subsequent dilutions up to a certain level
[8].
The serial sequential dilutions of the natural product at
6c, 30c, and 200c show emission maxima at 318nm rather
than the structured emission as observed with purest digi-
talis. This could arise due to the interference caused by other
inclusions in the samples.
Although, with the dilution, the peak intensity of the
compounds should gradually increase or decrease, the
gradualincreaseinemissionwithdilutionisduetoreduction
of self-quenching of ﬂuorophores as a result of concomitant
dilution. The decrease of emission with still further dilution
is caused by simple dilution eﬀect. Since the medicinally
active ingredients in serial dilution of drug are not detectable
by the common analytical methods in vogue, the results
cannot be compared with usual standard methodologies.
The Au voltammograms of the drug samples are shown
in Figures 3(a)–3(f).These voltammograms clearly indicate
the presence of a redox pair showing distinct peak potentials,
at ∼0.25 and 0.35 volt with Au electrode and ∼0.35 and
0.45 volt with bare Au electrode, respectively. The same
redox pair is seen with the medicinally active pure deriva-
tive Digoxin. Perfect reversible cyclic voltammograms are
obtained with the Au electrode. Interestingly, for both Au
and bare Au cases we got the same potential separation for
the cathodic and anodic peak. The cyclic voltammograms
indicate the presence of the peak for Digoxin (purest
medicinalderivativeofDigitalispurpurea)atthesamelevelas
that of serially ultradiluted drugs. This indicates the presence
of Digoxin-like substance in the ultradiluted samples of
the drug. As the structure in Figure 1 indicates, the ﬁve-
member moiety containing α,β-unsaturated carbonyl moi-
etyisresponsibleforacceptingoneelectronduringreduction
in the cyclic voltammogram.
5. Conclusion
Fluorescence spectroscopy and cyclic voltametry both can
be used to identify Digitalis purpurea and its derivatives, in
commercially available serially ultradiluted solutions.
6. Limitationsof the Study
The study has several limitations. Serial ultradilutions
beyond 200 have not been tried. Dilutions made out of
Digitalis purpurea θ were not tried as the same are not avail-
able commercially. Medicinally active ingredients of serial
ultradilutions of drugs are diﬃcult to detect analytically
in laboratory. Commercially available medicines were only
tried. Quantitative estimation of the active ingredients of the
drugs has not been made. Drugs in serial ultradilutions are
not detectable in biological specimen, bringing limits to the
design of the research. The glassy carbon electrodes were
used initially for cyclic voltammetry, which did not show
identiﬁcation/detection of the drug in serial ultradilution.
The obtained data/results with glassy carbon and Au elec-
trodes are not presented in this paper.
7.FutureScope
A comparative analysis of levels of proportional bulk con-
centration using the Randle-Sevcik relationship may be
p e r f o r m e d .T h e s et e c h n i q u e sm a yp r o v ev a l u a b l ei ns t a n -
dardization of diluted drugs as used in complementary and
alternative medicine. Fluorescence spectra and the redox
patterns indicate changes arising out of the serial dilution,
which may form the basis of future studies. Both these
techniques may be useful for the point-of-care services in
cases where patients are being “Digitalized,” in cases of
“poisoning with Digitalis,” and for toxicological studies of
Digitalis purpurea in nonbiological samples and its active
derivatives. This would enable physicians to take posological
and antitoxic measures.
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